Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma (scientific article published on 03 October 2019)

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Q50046367

Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.

Q52718431

The immune contexture of hepatocellular carcinoma predicts clinical outcome.

Q55180095

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Q56373211

The protein histidine phosphatase LHPP is a tumour suppressor.

Q58450463

Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy

Q58612842

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma

Q63859552

The statistics of synergism

Q74591572

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Q89012806

Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction

Q93099771

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Q24633214

New strategies in chronic lymphocytic leukemia: shifting treatment paradigms

Q26828496

Sorafenib in advanced hepatocellular carcinoma

Q27861075

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Q28296761

Drug combination studies and their synergy quantification using the Chou-Talalay method

Q29617422

limma powers differential expression analyses for RNA-sequencing and microarray studies

Q29617988

Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids

Q31542532

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

Q33893704

HISAT: a fast spliced aligner with low memory requirements

Q34043398

Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells

Q34354339

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

Q34384848

NF-κB-induced KIAA1199 promotes survival through EGFR signalling

Q34563758

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

Q35156866

Cancer cell spheroids as a model to evaluate chemotherapy protocols

Q36312156

Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma

Q36622264

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

Q36918248

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Q37226729

The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment

Q37595291

Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma

Q37617052

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

Q37688439

Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.

Q38723944

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Q38785510

PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression.

Q38790070

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

Q38808099

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

Q38812372

Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma

Q38829170

Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Q39612275

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

Q39883398

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Q40050634

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

Q40076996

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Q40231174

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.

Q41923187

Ibrutinib repurposing: from B-cell malignancies to solid tumors

Q42267801

Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.

Q42323382

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Q42775676

P4510

describes a project that uses

ImageJ

limma

issue

language of work or name

English